	US 11,939,380 B2
	Combination therapies targeting PD-1, TIM-3, and LAG-3
Trine Lindsted, Farum (DK); Michael Monrad Grandal, Ballerup (DK); Eva Maria Carlsen Melander, Malmö (SE); Camilla Fröhlich, København Ø (DK); Mikkel Wandahl Pedersen, Allerød (DK); Michael Kragh, Copenhagen N (DK); Johan Lantto, Lund (SE); Monika Gad, Allerød (DK); and Ivan David Horak, West Orange, NJ (US)
Assigned to LES LABORATOIRES SERVIER, Suresnes (FR)
Appl. No. 16/500,918
Filed by SYMPHOGEN A/S, Ballerup (DK)
PCT Filed Apr. 5, 2018, PCT No. PCT/EP2018/058752 § 371(c)(1), (2) Date Oct. 4, 2019, PCT Pub. No. WO2018/185232, PCT Pub. Date Oct. 11, 2018.
Claims priority of provisional application 62/481,973, filed on Apr. 5, 2017.
Prior Publication US 2020/0407444 A1, Dec. 31, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); A61K 2039/507 (2013.01); A61K 45/06 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

16 Claims

1. A method of enhancing immunity in a human patient in need thereof, comprising administering to the patient pembrolizumab or nivolumab in combination with an anti-TIM-3 antibody or an antigen-binding portion thereof that comprises:

a) H-CDR1-3 and L-CDR1-3 that comprise the amino acid sequences of SEQ ID NOs: 8-13, respectively;

b) a heavy chain variable domain (VH) and a light chain variable domain (VL) that comprise the amino acid sequences of SEQ ID NOs: 7 and 4, respectively; or

c) a heavy chain (HC) that comprises the amino acid sequences of SEQ ID NOs: 7 and 377 and a light chain (LC) that comprises the amino acid sequences of SEQ ID NOs: 4 and 378.